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The aim of this thesis is to evaluate the consequences of various immunosuppressive 
regimens on (long-term) side effects and on graft histology after pediatric liver 
transplantation. 
One of the consequences of immunosuppressive medication is an increased risk 
on post-transplantation malignancies. Post transplant lymphoproliferative disease 
(PTLD) is the most frequent malignancy in children after liver transplantation (LTx). 
PTLD is in most cases associated with the Epstein Barr virus (EBV). Chapter 2 de-
scribes the results of a prospective study in which monitoring EBV DNA in blood 
samples of pediatric liver transplant recipients was assessed in relation to the occur-
rence of primary EBV infection and the development of PTLD. Every 4 weeks after 
LTx a quantitative polymerase chain reaction (PCR) assay for EBV nuclear antigen-1 
was performed in 13 patients transplanted in 2000 or 2001. Patients were followed 
for development of PTLD. Before LTx, four patients were EBV seropositive and nine 
patients were EBV seronegative. �n one of the four patients who were EBV seroposi-
tive before LTx, EBV DNA became detectable after transplantation, indicating a reac-
tivation of viral replication. However, none of these four pre-transplant seropositive 
patients developed PTLD after LTx. Eight of the nine patients who were EBV serone-
gative before LTx developed positive EBV DNA samples within the first half year after 
LTx. EBV DNA was first detected at a median of 64 days after transplantation (range 
38-89). The median peak EBV DNA load was 20,600 copies/ml (3,600-466,000). Two 
of these patients developed PTLD, but they could not be identified based on prior 
or concomitant EBV PCR results. The majority of pediatric patients underwent a 
primary EBV infection after LTx. We found a high circulating EBV DNA load in these 
children. The circulating EBV DNA load can be used as a parameter to follow the 
development of the EBV infection, and may reflect a parameter for the immunosup-
pressive balance needed to control the EBV infection. 
Calcineurin blockers, like cyclosporine A (CsA) and tacrolimus (TAC) are associa-
ted with other side effects than the development of post-transplant malignancies. 
Nephrotoxicity is one of the most serious side effects of calcineurin blockers. Pedi-
atric patients face long-term, probably even life-long treatment with immunosup-
pressive medication. Reduction or withdrawal of immunosuppressive medication is 
expected to prevent or minimize the risk on side effects. �n Chapter 3 we describe a 
unique cohort of pediatric patients in whom we attempted to withdraw CsA during 
follow-up after LTx according to a strict protocol. �n this study CsA was withdrawn, 
at least 2 years after transplantation, in patients who had not experienced any re-
cent rejection of the liver graft. Between 1986 and 2001, 91 children received CsA for 
at least 2 years after LTx. �n 53 of the 91 children CsA was withdrawn. �n 35 patients 
(66%) withdrawal of CsA did not cause rejection. �n these patients the renal function 
improved compared with baseline values (glomerular filtration rate at 1 year, +16 
ml/min/1.73 m3, p <0.001; at 2 years: +11 ml/min/1.73 m3, p < 0.05). After CsA wit-
hdrawal, 18 patients developed a rejection (34%) which could be effectively treated 
by methylprednisolone and restarting CsA. Failure to withdraw CsA was not associa-
ted with increased incidence of graft loss. A body weight below 10 kg at the time of 
transplantation correlated significantly with successful withdrawal of CsA (< 10kg, 
85%; vs. > 10 kg, 60%; p<0.05). These data indicate that CsA can be withdrawn in a se-
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lected group of pediatric liver transplant patients from 2 years after transplantation 
with a success rate of approximately 70%. We found a significant improvement of 
the kidney function in patients in whom CsA was successfully withdrawn
One of the goals of successful LTx is the attainment of optimal final height. Many 
children have growth retardation before LTx. Several studies have indicated that 
growth retardation remained after LTx, while others reported catch-up growth. �m-
paired growth after LTx is often attributed to the use of corticosteroids. �n Chapter 4. 
we determined the relationship between end stage pediatric liver disease and LTx on 
the one hand and growth and final height on the other hand. �n a retrospective stu-
dy we evaluated growth during the first 2 years (n=101) and 5 years (n=63) after LTx. 
Height was expressed as a standard deviation score of the target height (ZTH score) of 
each individual patient. �n the first 2 years after LTx, the ZTH score significantly incre-
ased from -1.7 at LTx to -1.3 SD (p< 0.05). Growth between LTx and 2 or 5 years after 
LTx, expressed as Δ ZTH score was positively correlated with pre-transplant growth 
retardation (p<0.05). �n other words, those children who had the most severe growth 
retardation before transplantation had the most improvement of growth after LTx. 
The type of primary liver disease influenced the severity of growth retardation be-
fore LTx. Patients with a cholestatic primary liver disease were more severely growth 
retarded before LTx in comparison with a non-cholestatic primary liver disease (ZTH 
score -2.0 vs. -1.2 SD, p< 0.05), and had better growth in the first 2 years after LTx (Δ 
ZTH score +0.6 vs. -0.1 SD, p<0.05). Of the included patients, 80% used an immunosup-
pressive regimen that consisted of CsA, azathioprine and prednisolone, and 15% 
used an immunosuppressive scheme that consisted of TAC and prednisolone. The 
maintenance dosage of prednisolone was higher in the CsA-regimen compared with 
the TAC-regimen. Nevertheless, the changes in ZTH score were similar in the first two 
years after LTx (Δ ZTH score CsA: 0.3 ±1.1 SD, TAC: 0.3 ±1.1 SD).Twelve out of the 23 
patients who reached final height during the study period had a final height below 
-1.3 SD of their target height. Our data indicate that growth retardation is a com-
mon finding in children before LTx, particularly in children afflicted by a cholesta-
tic disease. Catch-up growth after LTx is related with growth retardation before LTx, 
and is predominantly observed in patients with a primary cholestatic liver disease. 
Catch up growth can predominantly be expected in the first two years after LTx. 
Based on our data we conclude that the use of prednisolone after transplantation is 
probably not the only cause responsible for persistently delayed growth in pediatric 
liver patients. Our longitudinal data indicate that after LTx in childhood, ~50% of 
patients reach a final height of less than -1.3 SD of their genetic potential. 
Pediatric LTx is still a relatively new treatment modality and relatively little infor-
mation is presently available on the long-term histology and function of the liver 
graft. �n Chapter 5 we describe the result of a study on graft histology up to ten years 
after LTx. Follow up after LTx was performed according to protocol, and included 
liver biopsies of transplanted pediatric patients at 1 year, 5 years and 10 years after 
LTx. CsA was the principle immunosuppressive medication. Peeters et al have de-
scribed the presence of portal fibrosis in 31% (n=84) of the grafts in protocol biopsies 
1 year after LTx 1. Using the same cohort of patients, we extended the analysis to 
follow-up protocol biopsies obtained 5 and 10 years after transplantation. From 1 
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year to 5 years after LTx, the prevalence of fibrosis increased from 31% to 65%, but 
remained stable thereafter (at 10 years, 69%). Whereas the prevalence of patients 
with some form of fibrosis stabilized at 5 years, the severity of fibrosis increased 
between 5 and 10 years after transplantation. At 10 years after LTx, the percent-
age of patients with severe fibrosis had increased from 10% (at 5 years) to 29%. At 
1 year after LTx 69% of the biopsy specimens did not show fibrosis. However two 
third of these patients (64%) had developed some degree of fibrosis after the first 
year of follow-up (“late” fibrosis). Transplant associated factors were related to the 
development of fibrosis after LTx, both “early” (< 1 year) and “late” fibrosis. �denti-
fied factors are a prolonged cold ischemia time, young age at the time of transplan-
tation, high donor/recipient age ratio and the use of partial grafts. Fibrosis is not 
associated with the occurrence of rejection, chronic hepatitis or the withdrawal of 
CsA 2 years after LTx. The development of fibrosis did not affect the function of the 
transplanted liver nor the graft survival up to ten years. �t is obviously still unclear 
what the natural course of the fibrosis beyond 10 years after LTx will be, but the 
present results underline the value of continued protocol biopsies to better under-
stand and predict the long-term graft function and histology after pediatric LTx. 
Theoretically the development of fibrosis could be due to low-grade ongoing rejec-
tion that occurs below the level of biochemical or clinical detection. TAC is known to 
have a stronger immunosuppressive profile than CsA 2 �f indeed (part of) the fibrosis 
was due to under-immunosuppression, one would expect that the introduction of 
tacrolimus (TAC) -based immunosuppressive regimens would decrease the rate of 
fibrosis after transplantation. TAC is known to have a stronger immunosuppressive 
profile than CsA 2. �n chapter 6 we report on graft histology at 1 year after LTx in 
pediatric patients who used TAC as main immunosuppressive medication. Patients 
transplanted between 1999 and 2006, with at least 1 year post LTx survival and who 
used a TAC-based immunosuppressive scheme were included in the study. A 1 year 
post LTx protocol biopsy was available in 74 of the 77 included patients. Compared 
with our earlier study with a CsA-based immunosuppressive regimen, the preva-
lence of fibrosis was similar (TAC 35%; CsA 31%, NS). We observed histological hepa-
titis more frequently in patients who used TAC (22%) compared with the CsA group 
(CsA 1%; p< 0.001). The histological hepatitis was predominantly graded as mild 
according to the METAV�R scoring system (75% mild, 25% moderate) and was not 
associated with elevated liver enzymes. Twelve of these sixteen patients had signs 
of an active viral infection, either EBV or CMV. �mmuno-staining of the liver tissue 
with EBV encoded RNA (EBER) in situ hybridisation however, was negative in all 
hepatitis cases. Nevertheless the histological hepatitis seems rather due to over-im-
munosuppression than to under-immunosuppression. Our present results indicate 
that neither over- nor under-immunosuppression is a major contributor to the high 
prevalence of graft fibrosis at 1 year post-transplantation. 
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Conclusions 
The results in the present thesis indicate that pediatric LTx has matured to an accep-
table treatment modality for end stage liver disease. Our findings also indicate that 
the individual prognosis after LTx still knows variability, partly based on patient 
related factors. �t may become the greatest challenge in the future to develop post-
transplant surveillance and treatment regimens which may account for the indivi-
dual variability. 
�t seems that the (risk on) side effects of immunosuppression such as the develop-
ment of PTLD can be minimized by pre-emptive therapy: lowering the dose of calci-
neurin blockers in patients at risk. Patients at risk may be identified by a high EBV 
DNA. Mc Diarmid demonstrated that the use of pre-emptive therapy decreased the 
incidence of PTLD in pediatric patients after LTx from 10 to 5%.3 The concurring 
counterpart of this strategy however, is that this increases the risk of rejection of the 
transplanted graft. �ndividualized and stringent monitoring holds promise. Reduc-
tion of immune suppression in patients with a high EBV DNA load can be installed 
without rejection4 or with rejection in only a small percentage of patients.5 Based on 
these observations, a high EBV DNA load could reflect an over-immunosuppressed 
condition, in which reduction of immunosuppression could re-establish the T-cell 
control function and prevent PTLD. �t remains to be determined to what level and for 
what duration the dose of immunosuppression has to be adjusted. We have shown 
that the majority of pediatric patients undergo an EBV infection the first half year 
after LTx. A high circulating EBV DNA load can be found in patients who develop a 
PTLD, as well as in patients with an uncomplicated primary EBV infection. Our data 
indicate that such a pre-emptive therapy would not only lead to reduction of im-
munosuppression in patients, who may develop PTLD, but also in patients, who will 
spontaneously recover. We still need more precise tools to predict patients at risk of 
developing PTLD and to evaluate the effect of pre-emptive therapy on the immuno-
suppressive state of each individual patient. 
We have shown that in a majority of a selected group of pediatric patients calcineu-
rin blockers (cyclosporine A) can be withdrawn two years after transplantation. We 
found a significant improvement of the kidney function in these patients. �t has 
been shown that there is a further impairment of kidney function in time with the 
use of calcineurin inhibitors.6 Withdrawal of CsA could therefore not only improve 
renal function but could also prevent further decline of renal function. Withdrawal 
of CsA was more successful in the younger patients. The liver is the most immuno-
tolerant organ in solid organ transplantation, which means that patients after LTx 
need less immunosuppressive medication than after transplantation of other so-
lid organs. �n 20%-25% of the patients in whom immunosuppression was stopped 
(as in PTLD or inadvertently, upon non-adherence to treatment) liver function was 
well maintained without restarting medication.7 Our present results suggest that 
especially young children who are transplanted at a younger age (below 2 years of 
age) will have a higher change on developing immuno-tolerance of the transplanted 
liver. The pediatric immune system may be more amenable to tolerance than that of 
adults, caused by more circulating naive T cells and a still full functional thymus.8 
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CsA could be withdrawn at the cost of a higher prednisolone dose, but the differ-
ence in prednisolone dosage between the group in which CsA was withdrawn and 
the group in which CsA was continued was relatively modest. The higher dose of 
prednisolone did not result in a difference in height.
Growth delay after LTx is often attributed to the use of corticosteroids. Our data 
suggest that the use of prednisolone might not be the only cause of the persistently 
delayed growth in pediatric liver transplant patients. We have shown that growth 
retardation in children with LTx mainly originates in the period before LTx. After 
LTx there is some catch-up growth in the youngest and most severely growth retar-
ded patients, which correlates with a primary cholestatic liver disease. After LTx in 
childhood, ~50% of patients reach a final height of less than -1.3 SD of their genetic 
potential. �mproving final height of children that are candidates for LTx should al-
ready start at the period before LTx. Growth retardation before LTx might be due to 
malabsorption caused by liver insufficiency and/or insufficient intake of energy and 
proteins.9 This possibility is supported by the observation that growth retardation 
was especially prominent in patients with a primary cholestatic liver disease. �n ad-
dition, endocrine factors may also play a part in the poor growth observed in child-
ren with chronic liver disease. The liver produces insulin-like growth factor-� (�GF-�) 
and �GF-binding proteins. Also, growth hormone is degraded in the liver. �n patients 
with chronic liver disease, increased levels of growth hormone and decreased levels 
of �GF-1 and �GF-B3 have been described.10-13 A decrease in �GF-l level and GH insensi-
tivity may be secondary to a combination of impaired hepatic function and protein 
calorie malnutrition.
Long term survival after LTx is not only determined by side effects of medication but 
also by long term function of the transplanted liver. We found mild to severe graft 
fibrosis in the majority of a cohort of pediatric patients 10 years after LTx. Although 
liver function was still preserved in these patients, the long-term prognosis of liver 
grafts with severe fibrosis or cirrhosis seems worrisome. Fibrosis was associated with 
a prolonged cold ischemia time (C�T), young age at the time of transplantation, high 
donor/recipient age ratio and the use of partial grafts. The origin and pathofysiolo-
gical mechanism underlying the fibrosis is still unclear. Our data show that a long 
C�T contributes to the development of fibrosis in pediatric liver grafts. The biliary 
tree seems to be more vulnerable for a prolonged C�T than the liver parenchyma, 
which subsequently could lead to more ischemic damage and fibrosis in the portal 
tracts. The development of fibrosis could theoretically reflect subclinical biliary ste-
nosis which eventually manifests. Our present data, however, do not provide positive 
indications for this possibility.
Conversely, the contribution of a long C�T to fibrosis could be caused by confoun-
ding factors. For example, a long C�T could represent the cut-down procedure for 
preparation of partial grafts. Young age is related to the use of partial grafts and a 
high donor/recipient age ratio. Partial grafts have to adjust to different blood flow 
and space after LTx. Partial grafts have to expand during growth, especially in small 
children. Growth of the transplanted partial graft under chronic immunosuppres-
sion could result in fibrosis.14 Fibrosis was not associated with withdrawal of CsA, 
which suggests that this process is relatively independent to the amount of immu-
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nosuppression. Our results differ from centers that have reported graft fibrosis in 
long- term biopsy specimens after LTx to be associated with chronic rejection or 
under-immunosuppression.14-16 
Presently, most pediatric patients use tacrolimus (TAC), which has a stronger im-
munosuppressive effect than CsA.2 We have shown, however, that the prevalence 
of fibrosis at 1 year after LTx is the same in a cohort of children who received a 
TAC- based regimen as in our previous cohort of patients, who received CsA.1 We 
also found a high prevalence of histological hepatitis in the cohort of patients that 
used TAC; this hepatitis was in the majority of patients associated with an active 
viral infection. Our present results support the concept that neither over- nor under-
immunosuppression is a major contributor to the high prevalence of graft fibrosis 
at 1 year post transplantation. Although fibrosis in our present study tended to be 
associated with younger age of the recipient, longer cold ischemia time, biliary com-
plications and the use of partial grafts, statistical significance was not reached, so 
our previous findings can not be confirmed in this study.
We clearly need more studies of long term graft histology to elucidate the cause of 
fibrosis in pediatric patients after LTx. We need to extend the follow-up studies to 
evaluate the long term consequences of pediatric LTx, in order to further improve 
long-term health for transplanted patients and to provide more detailed prognostic 
and predictive information to patients and their parents before LTx. 
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